Towards Healthcare Research & Consulting

Dried Blood Spot Collection Cards Market Size, Share, Forecast (2026-2035), Filter Paper Cards and Devices for Newborn Screening, Infectious Disease, Therapeutic Drug Monitoring and Remote Sampling

The dried blood spot collection cards market is estimated at USD 184.73 million in 2026 and is projected to reach USD 351.21 million by 2035, expanding at a CAGR of 7.40% from 2026 to 2035. The market was valued at USD 172.00 million in 2025, which is the base year. The market comprises cards and devices that collect capillary blood as dried spots, including cellulose filter paper cards, treated cards that stabilize DNA and RNA, and volumetric DBS devices, used for newborn screening, infectious disease testing, therapeutic drug monitoring and pharmacokinetics, genetic and biomarker testing. It also involves remote home sampling by public health and newborn screening laboratories, hospitals and clinics, pharmaceutical companies and CROs, and research and consumer testing laboratories. Standard Cellulose Cards accounted for the largest product share of 58.00% in 2025, because newborn screening programs use them for every baby.

Last updated 17 November 2026   |   Primary source: Towards Healthcare   |   Report: 7202   |   Derived values are labelled
USD 184.73 Mn
Revenue, 2026
USD 351.21 Mn
Forecast, 2035
7.40%
CAGR, 2026-2035
Global
Report Coverage

Key Takeaways

Dried Blood Spot Collection Cards Market Growth and Top Companies

Market Size & Growth Outlook

  • Market size in 2025: USD 172.00 million
  • Estimated market size in 2026: USD 184.73 million
  • Projected market size by 2035: USD 351.21 million
  • CAGR (2026-2035): 7.40%

Regional Market Spotlight

  • North America led the market with a 36.00% share in 2025.
  • Europe accounted for 28.00% of the market in 2025.
  • Asia Pacific held 25.00% of revenue in 2025 and is projected to grow at the highest CAGR of 8.43% during the forecast period.

Segmental Spotlight

  • By product, Standard Cellulose Cards accounted for a 58.00% share in 2025.
  • By application, Newborn Screening held 52.00% of revenue in 2025.
  • Public Health & Newborn Screening Labs captured a 50.00% share in the end-user segment in 2025.

The market is projected to grow from USD 172.00 million in 2025 to USD 351.21 million by 2035 because dried blood spots are cheap to collect and ship, and newborn screening programs use a card for nearly every baby. Newborn screening, home sampling, decentralized trials and new screening programmes support steady growth, lifting the market to USD 245.78 million by 2030 and sustaining a CAGR of 7.40% from 2026 to 2035. DBS sampling supports genomics, precision medicine and telehealth-based home testing.

Dried Blood Spot Collection Cards Market Size is USD 184.73 Million in 2026.

Analyst View: We built the estimate from newborn births screened, DBS use in trials, home testing and infectious disease programmes and average card prices by region, cross-checked against supplier activity. Published estimates for this exact scope are limited, so our value is evidence-based.

  • Volumetric DBS devices are helping in the improvement of accuracy and consistency of blood sample collection.
  • Home-based blood collection is expanding the use of DBS cards as it enables samples to be collected conveniently outside clinical settings.
  • The growth of decentralized clinical trials is fueling the demand for DBS cards that reduce intricacies involved in the process of remote sample collection and transportation.
  • Expansion of newborn panels and genomic screening ecosystem is increasing the use of DBS cards for timely detection of genetic and metabolic disorders.
  • Type 1 diabetes screening is expanding the application base for DBS in the collection and analysis of blood samples.
  • Advancements in sample preparation help to improve room-temperature stability of dried blood samples.

Drivers, Restraints and Opportunities

Market Drivers - Impact & CAGR Contribution (2026-2035)

Driver Impact ≈ CAGR Contribution Time Horizon Key Regions
Universal newborn screening High +2.89 pp Short to long term Global, strongest in North America
Home sampling grows Medium +2.44 pp Medium to long term Global, fastest uptake in Asia Pacific
Decentralised trials Medium +2.08 pp Short to medium term Global
Remote infectious disease testing Low +1.63 pp Long term Developed and emerging markets

Note: Contributions are indicative estimates of each factor's effect on annual growth.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Taken together, these drivers add about 9.03 percentage points to the annual growth of the dried blood spot collection cards market, with universal newborn screening having the largest effect. Their influence is strongest in North America, while uptake grows fastest in Asia Pacific.

Market Restraints - Impact & Negative CAGR Contribution (2026-2035)

Restraint Impact ≈ Negative CAGR Contribution Time Horizon Key Regions
Haematocrit effects on accuracy High -0.73 pp Short to medium term Global
Analyte stability limits High -0.54 pp Medium term Price-sensitive and emerging markets
Lab validation burden Medium -0.36 pp Short term North America and other mature markets

Note: Contributions are indicative estimates of each factor's effect on annual growth.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

These restraints are expected to reduce annual growth of the dried blood spot collection cards market by about 1.63 percentage points, led by haematocrit effects on accuracy. Their effect eases over the forecast period as suppliers, buyers and regulators adapt, leaving a net CAGR of 7.40% from 2026 to 2035.

Opportunity

Volumetric DBS devices are being increasingly adopted, which creates opportunities for accurate and standardized blood sample collection. The expansion of newborn screening programs in Asia is fueling the demand for DBS cards in early disease detection. Rising use of type 1 diabetes and genomic screening drives market demand in specialized testing applications. Growing interest in preventive healthcare is creating opportunities for the use of DBS cards in at-home health testing kits. The demand for biobanking is increasing, which fuels the adoption of DBS cards to facilitate long-term sample collection, preservation, and storage.

Market Segmentation: 2025 Share and Value

Dried Blood Spot Collection Cards Market by Product 2025 Share

Dried Blood Spot Collection Cards Market, By Product, Segment Dominates by 58% in 2025.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

Standard Cellulose Cards accounted for 58.00% of the market in 2025 and are projected to expand at a CAGR of 6.55% during the forecast period. Standard cellulose cards lead because newborn screening programmes use them for every baby. This segment is expected to grow slower than the overall market between 2026 and 2035.

Treated & Nucleic Acid Cards stabilise DNA and RNA for genetic and infectious disease tests. This segment is expected to grow at a slower rate than the overall market over the forecast period.

Volumetric DBS Devices grow fastest because they collect a fixed blood volume for accurate drug and biomarker tests. The volumetric DBS devices segment is expected to grow faster than the overall market from 2026 to 2035.

Segment Outlook: Standard Cellulose Cards remains the largest product segment through 2035, holding about 53.59% of the market in 2035, while Volumetric DBS Devices records the highest CAGR of 9.95% from 2026 to 2035. Although Volumetric DBS Devices starts from the smallest base, its faster growth shows how demand is shifting within the dried blood spot collection cards market.

Dried Blood Spot Collection Cards Market by Application 2025 Share

Dried Blood Spot Collection Cards Market, By Application, Segment Dominates by 52% in 2025.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Newborn Screening held a 52.00% share in 2025 and is projected to expand at a CAGR of 6.90% from 2026 to 2035. Newborn screening leads because nearly all births in many countries are screened with DBS cards. This segment is expected to grow slower than the overall market over the forecast period.

Infectious Disease Testing uses DBS for HIV and hepatitis in remote areas. The infectious disease testing segment is expected to grow broadly in line with the overall market between 2026 and 2035.

Therapeutic Drug Monitoring & PK grow the fastest in trials. This segment is expected to grow faster than the market from 2026 to 2035.

Genetic & Biomarker Testing uses DBS for home sampling. The genetic & biomarker testing segment is expected to grow broadly in line with the overall market over the forecast period.

Others uses include research. This segment is expected to grow broadly in line with the market from 2026 to 2035.

Segment Outlook: Newborn Screening remains the largest application segment through 2035, holding about 49.63% of the market in 2035, while Therapeutic Drug Monitoring & PK records the highest CAGR of 9.30% from 2026 to 2035. Others holds the smallest share today and serves more specialised needs within the dried blood spot collection cards market.

Dried Blood Spot Collection Cards Market by End User 2025 Share

Dried Blood Spot Collection Cards Market, By End User, Segment Dominates by 50% in 2025.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

Public Health & Newborn Screening Labs accounted for 50.00% of the dried blood spot collection cards market in 2025 and is projected to expand at a CAGR of 6.85% from 2026 to 2035. Public health and newborn screening labs lead because they buy cards in national volumes. This segment is expected to grow slower than the overall market over the forecast period.

Hospitals & Clinics segment is expected to grow broadly in line with the overall market between 2026 and 2035.

Pharma Companies & CROs are growing the fastest with decentralised trials. The pharma companies & CROs segment is expected to grow faster than the overall market over the forecast period.

Research & Consumer Labs use home kits, the research & consumer labs segment is expected to grow broadly in line with the overall market from 2026 to 2035.

Segment Outlook: Public Health & Newborn Screening Labs remains the largest end user segment through 2035, holding about 47.50% of the market in 2035, while Pharma Companies & CROs record the highest CAGR of 9.25% from 2026 to 2035. Research & Consumer Labs holds the smallest share today and serves more specialised needs within the dried blood spot collection cards market.

Analyst View: Segment shares were allocated from demand, product portfolios and pricing in each category. Standard Cellulose Cards, Newborn Screening and Public Health & Newborn Screening Labs lead their categories because they meet the core needs of today's buyers. We expect Volumetric DBS Devices, Therapeutic Drug Monitoring & PK and Pharma Companies & CROs to gain share as newer technologies, users and applications grow faster.

Regional Analysis

Dried Blood Spot Collection Cards Market Shares for North America, Europe, Asia Pacific, Latin America and Middle East and Africa, 2025 (%).

Dried Blood Spot Collection Cards Market by Region 2025 Share

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

North America accounted for 36.00% of the market in 2025 and is projected to expand at a CAGR of 6.83% from 2026 to 2035. North America leads because of universal newborn screening, decentralized trials and home testing companies. North America is expected to grow slower than the overall market over the forecast period.

Europe has national newborn screening and new type 1 diabetes and genomic screening pilots. Europe is expected to grow broadly in line with the overall market throughout the forecast period.

Asia Pacific grows fastest as newborn screening expands in China, India and Southeast Asia. Asia Pacific is expected to grow faster than the market over the forecast period.

Latin America has an expanding newborn screening ecosystem. This region is expected to grow broadly in line with the overall market between 2026 and 2035.

Middle East & Africa use DBS for HIV and newborn programs. This region is expected to grow broadly in line with the overall market over the forecast period.

Analyst View: Regional shares were built from demand, installed base, spending and supplier presence in each region. North America leads because of its mature demand base and strong suppliers. We assign Asia Pacific the highest growth premium because investment, adoption and capacity are expanding fastest there.

Competitive Landscape

Top 10 Companies in the Dried Blood Spot Collection Cards Market, 2025

Dried Blood Spot Collection Cards Market Companies are Revvity, Cytiva (Danaher), Ahlstrom, Neoteryx (Trajan), Capitainer, Tasso, Thermo Fisher Scientific, ID Biological Systems, Spot On Sciences, Hemaxis

Rank Company Name 2025 Share (%) Key Products / Business Headquarters
1 Revvity 12.79% Newborn screening cards and GSP systems United States
2 Cytiva (Danaher) 11.63% Whatman 903 protein saver and FTA cards United States
3 Ahlstrom 6.98% Filter paper DBS cards Finland
4 Neoteryx (Trajan) 4.65% Mitra VAMS volumetric devices Australia
5 Capitainer 2.33% qDBS volumetric cards Sweden
6 Tasso 2.33% Tasso-M20 dried volumetric blood collection United States
7 Thermo Fisher Scientific 1.74% DBS collection products United States
8 ID Biological Systems 1.74% Specimen collection cards United States
9 Spot On Sciences 1.16% HemaSpot blood collection devices United States
10 Hemaxis 1.16% Hemaxis DB10 volumetric device Switzerland

Note: Company shares are 2025 estimates.

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Revvity led the market with 12.79% of revenue in 2025, followed by Cytiva (Danaher) at 11.63% share and Ahlstrom at 6.98% share. Revvity is the leader owing to newborn screening cards and GSP systems, Cytiva (Danaher) competes with Whatman 903 protein saver and FTA cards, and Ahlstrom offers filter paper DBS cards. Neoteryx (Trajan), Capitainer, Tasso, Thermo Fisher Scientific, ID Biological Systems, Spot On Sciences and Hemaxis compete through Mitra VAMS volumetric devices, qDBS volumetric cards, Tasso-M20 dried volumetric blood collection, DBS collection products, specimen collection cards, hemaSpot blood collection devices and hemaxis DB10 volumetric device. The top 10 companies accounted for a 46.51% share in 2025, while the remaining 53.49% was shared among many regional card printers and kit assemblers. The market is concentrated among a few filter paper suppliers, and competition revolves around paper consistency, regulatory clearance, volumetric accuracy, stability, program contracts and price.

Company Snapshots

Revvity: Revvity is headquartered in the United States. It held 12.79% of revenue in 2025. Its offering revolves around Newborn screening cards and GSP systems. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

Cytiva (Danaher): Cytiva (Danaher) has its global headquarters in the United States. It held an 11.63% share in 2025. Its offering centres on Whatman 903 protein saver and FTA cards. Cytiva (Danaher) is positioned as a Leader in the Towards Healthcare Companies Quadrant.

Ahlstrom: Ahlstrom has its corporate headquarters in Finland. The company held an 6.98% share of the dried blood spot collection cards market in 2025. Its offering centres on Filter paper DBS cards. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

Neoteryx (Trajan): Neoteryx (Trajan) is headquartered in Australia. It held 4.65% of the market in 2025. Its offering revolves around Mitra VAMS volumetric devices. The company has been positioned as a Leader in the Towards Healthcare Companies Quadrant.

Capitainer: Capitainer is headquartered in Sweden. Capitainer held a 2.33% share of the dried blood spot collection cards market in 2025. Its offering centres on qDBS volumetric cards. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

Tasso: Tasso has its corporate headquarters in the United States. It held 2.33% of revenue in 2025. Its portfolio consists of Tasso-M20 dried volumetric blood collection. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

Thermo Fisher Scientific: Thermo Fisher Scientific is headquartered in the United States. It held a 1.74% share in 2025. Its offering centres on DBS collection products. Thermo Fisher Scientific is positioned as a Innovator in the Towards Healthcare Companies Quadrant.

ID Biological Systems: ID Biological Systems has its global headquarters in the United States. It held 1.74% of the market in 2025. Its offering revolves around Specimen collection cards. In the Towards Healthcare Companies Quadrant it is positioned as an Innovator.

Spot On Sciences: Spot On Sciences has its corporate headquarters in the United States. It held 1.16% of revenue in 2025. The company’s portfolio comprises HemaSpot blood collection devices. The company has been positioned as an Innovator in the Towards Healthcare Companies Quadrant.

Hemaxis: Hemaxis, part of DBS System SA, is headquartered in Switzerland. It held a 1.16% share in 2025. Its offering centres on Hemaxis DB10 volumetric device. In the Towards Healthcare Companies Quadrant it is positioned as an Innovator.

Companies Ecosystem

The dried blood spot collection cards ecosystem links paper & material suppliers, card & device makers, kit assemblers, users and regulators, with each stage adding value before products reach end users.

Ecosystem Stage Role in the Market Key Companies
Paper & Material Suppliers Make filter paper Cytiva, Ahlstrom
Card & Device Makers Make cards and volumetric devices Revvity, Trajan, Capitainer
Kit Assemblers Build home and trial kits Kit and logistics firms
Users Collect and test samples Newborn labs, hospitals, CROs, consumer labs
Regulators Clear devices and set screening rules FDA, CLSI NBS01, EU IVDR

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Paper & Material Suppliers: Make filter paper. Key participants include Cytiva, Ahlstrom.

Card & Device Makers: Make cards and volumetric devices. Key participants include Revvity, Trajan, Capitainer.

Kit Assemblers: Build home and trial kits. Key participants include Kit and logistics firms.

Users: Collect and test samples. Key participants include Newborn labs, hospitals, CROs, and consumer labs.

Regulators: Clear devices and set screening rules. Key participants include FDA, CLSI NBS01, EU IVDR.

Value in the dried blood spot collection cards market flows from upstream material and technology suppliers to manufacturers and service providers, then through distribution partners to end users. Companies that integrate several stages or build long-term relationships with end users capture a larger share of this value.

Towards Healthcare Companies Quadrant

The Towards Healthcare Companies Quadrant positions key participants in the dried blood spot collection cards market by market strength, reflecting revenue scale, market share and geographic reach, and by innovation and growth strategy, reflecting product portfolio breadth, research and development intensity, and partnerships. Positions reflect each company's estimated 2025 share of the dried blood spot collection cards market and our assessment of its product innovation, portfolio breadth, and partnerships.

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Leaders: Revvity, Cytiva (Danaher), Ahlstrom, Neoteryx (Trajan), Capitainer and Tasso combine high market share with broad portfolios and strong innovation.

Innovators: Thermo Fisher Scientific, ID Biological Systems, Spot On Sciences and Hemaxis bring newer technologies and specialised products.

Recent Developments

  • September 2026: Revvity launched its CE-IVDR-certified GSP T1D 3plex kit for population screening of early type 1 diabetes using capillary dried blood spots on its GSP instrument.

Market Segments

By Product

  • Standard Cellulose Cards
  • Treated & Nucleic Acid Cards
  • Volumetric DBS Devices

By Application

  • Newborn Screening
  • Infectious Disease Testing
  • Therapeutic Drug Monitoring & PK
  • Genetic & Biomarker Testing
  • Others

By End User

  • Public Health & Newborn Screening Labs
  • Hospitals & Clinics
  • Pharma Companies & CROs
  • Research & Consumer Labs

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Spain, Rest of Europe)
  • Asia Pacific (China, Japan, India, South Korea, Taiwan, Rest of Asia Pacific)
  • Latin America (Brazil, Argentina, Rest of Latin America)
  • Middle East & Africa (GCC, South Africa, Rest of MEA)

Research Methodology

The market is defined as cards and devices that collect capillary blood as dried spots, including cellulose filter paper cards, treated cards that stabilize DNA and RNA, and volumetric DBS devices, used for newborn screening, infectious disease testing, therapeutic drug monitoring and pharmacokinetics, genetic and biomarker testing, and remote home sampling by public health and newborn screening laboratories, hospitals and clinics, pharmaceutical companies and CROs, and research and consumer testing laboratories. The 2025 base year was built bottom-up from demand volumes and average prices by product, application and end user and region, and checked top-down against the market-specific revenues of leading companies and published estimates. Segment, regional and company values were allocated from product, application and end user and region demand. Key estimates were verified by cross-checking company disclosures, regulatory and industry data and published third-party estimates, and inputs that could not be reconciled were excluded. All segment, regional and company figures were reconciled to the same 2025 base year, and the 2026-2035 forecast, which applies a constant CAGR from the 2025 base, was recalculated and validated.

Analyst View: The market is set for steady expansion as newborn screening and related demand keep growing. Our estimate links value to underlying demand, installed base and pricing, so the forecast follows real adoption rather than headline hype. The main upside comes from volumetric devices and new screening programmes, while the main risks are haematocrit effects and analyte stability limits.

References

Meet the Team

Payal Rabde

Payal Rabde

Principal Consultant

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde
Aditi Shivarkar

Aditi Shivarkar LinkedIn

Reviewed By

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar